VRP Verona Pharma Plc

Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference.

An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com.  A replay of the webcast will be made available for 90 days following the presentation.

Event: Wedbush PacGrow Healthcare ConferenceDate: August 15, 2017Time: 3:05 PM EDT Location: New York, NY

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plc				Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer				info@veronapharma.com
N+1 Singer (Nominated Adviser and UK Broker)				Tel: +44 (0)20 7496 3000
Aubrey Powell / James White
FTI Consulting (UK Media and Investor enquiries)				Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins				veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
James Heins				Tel: +1 203-682-8251James.Heins@icrinc.com
Stephanie Carrington				Tel. +1 646-277-1282Stephanie.Carrington@icrinc.com